Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$47 Mln
P/E Ratio
--
P/B Ratio
38.44
Industry P/E
--
Debt to Equity
-0.07
ROE
-7.3 %
ROCE
215.88 %
Div. Yield
0 %
Book Value
--
EPS
-0.31
CFO
$-132.29 Mln
EBITDA
$-180.28 Mln
Net Profit
$-191.50 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
VolitionRX (VNRX)
| -18.33 | -10.91 | -22.22 | -42.35 | -43.31 | -34.71 | -18.15 |
|
BSE Sensex*
| 0.49 | 0.83 | 3.20 | 6.47 | 11.19 | 20.21 | 11.10 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
VolitionRX (VNRX)
| -16.54 | -70.37 | -22.61 | -19.28 | -17.93 | 161.88 | -38.27 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.21 | 10,135.98 | 20.78 | 23.13 | |
| 302.88 | 8,668.61 | 21.55 | 58.42 | |
| 27.39 | 9,559.25 | -- | -28.77 | |
| 105.76 | 10,030.35 | 30.81 | 14.16 |
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and diseases associated with NETosis such as sepsis in the United States and internationally. It... offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis such as sepsis; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada. Address: 1489 West Warm Springs Road, Henderson, NV, United States, 89014 Read more
Executive Chairman
Dr. Martin Charles Faulkes Ph.D.
Founder, CEO, President & Director
Mr. Cameron Reynolds MBA
Headquarters
Henderson, NV
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of VolitionRX Limited (VNRX) stood at $ 9 Mln as on 31-Dec-24
The share price of VolitionRX Limited (VNRX) is $0.49 (NYSE) as of 24-Apr-2025 16:10 EDT. VolitionRX Limited (VNRX) has given a return of -43.31% in the last 3 years.
VolitionRX Limited (VNRX) has a market capitalisation of $ 47 Mln as on 24-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of VolitionRX Limited (VNRX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the VolitionRX Limited (VNRX) and enter the required number of quantities and click on buy to purchase the shares of VolitionRX Limited (VNRX).
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and diseases associated with NETosis such as sepsis in the United States and internationally. It offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis such as sepsis; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada. Address: 1489 West Warm Springs Road, Henderson, NV, United States, 89014
The CEO & director of Dr. Martin Charles Faulkes Ph.D.. is VolitionRX Limited (VNRX), and CFO & Sr. VP is Mr. Cameron Reynolds MBA.
There is no promoter pledging in VolitionRX Limited (VNRX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| VolitionRX Limited (VNRX) | Ratios |
|---|---|
|
Return on equity(%)
|
164.89
|
|
Operating margin(%)
|
-2182.2
|
|
Net Margin(%)
|
-2186.27
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of VolitionRX Limited (VNRX) was $0 Mln.
$0.01
(
